RVAC Medicines

About:

RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas.

Website: https://www.rvacmed.com

Top Investors: EDBI, Pavilion Capital, C-Bridge Capital, GS Holdings

Description:

RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas. The company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. It's cutting-edge GMP manufacturing facilities that will advance its platform technologies through in-house research and development and external partnerships, enabling the production of cutting-edge mRNA and nucleic acid delivery technologies. RVAC Medicines was founded in 2021 and is based in Singapore.

Total Funding Amount:

$140M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Singapore, Central Region, Singapore

Founded Date:

2021-01-01

Contact Email:

info(AT)rvacmed.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2022-04-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai